Suppr超能文献

中期对开角型青光眼患者角膜内皮细胞的影响及 Preserflo MicroShunt 植入术的疗效 - 一项为期两年的前瞻性研究。

Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma - a prospective study over two years.

机构信息

University Eye Hospital Tuebingen, Centre for Ophthalmology, Elfriede-Aulhorn-Str. 7, Tübingen, 72076, Germany.

Institute for Ophthalmic Research, Centre for Ophthalmology, Tuebingen, Germany.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3661-3670. doi: 10.1007/s00417-024-06508-8. Epub 2024 May 21.

Abstract

INTRODUCTION

Preserflo MicroShunt is a novel microinvasive bleb forming device for the treatment of primary open-angle glaucoma. The intermediate- and long-term success and the impact of this procedure on corneal endothelial cell density remain to be investigated.

METHODS

In this prospective observational study, 62 eyes of 55 glaucoma patients (mean age ± SD: 67.0 ± 15.0 years) receiving a Preserflo MicroShunt were included. Corneal endothelial cell density, intraocular pressure and best corrected visual acuity were assessed preoperatively and at 3, 6, 9, 12, 18 and 24 months postoperatively. Success rates, bleb revision rates and complications were analysed. Complete success was defined as an intraocular pressure reduction of ≥ 20% and achieving a target pressure of ≤ 18, ≤ 15 or ≤ 12 mmHg without antiglaucoma medication. Qualified success indicated that the criteria were reached with or without medication.

RESULTS

Corneal endothelial cells showed no significant decline over 24 months (p > 0.05). Intraocular pressure showed a substantial reduction postoperatively (p < 0.001), decreasing from 29.6 ± 8,3 mmHg to 13.0 ± 4.3 mmHg after 24 months (p < 0.001). Complete and qualified success with a target pressure ≤ 15 mmHg was achieved in 52.9% and 54.6% of cases after 24 months, respectively. Best corrected visual acuity did not change after 24 months.

CONCLUSION

Preserflo MicroShunt had no negative side effects on corneal endothelial cells and showed favourable success rates after 2 years in patients with open-angle glaucoma.

摘要

简介

Preserflo MicroShunt 是一种新型微创滤泡形成装置,用于治疗原发性开角型青光眼。该手术的中期和长期成功率以及对角膜内皮细胞密度的影响仍有待研究。

方法

在这项前瞻性观察研究中,纳入了 55 名青光眼患者(67.0±15.0 岁)的 62 只眼,这些患者接受了 Preserflo MicroShunt 治疗。术前和术后 3、6、9、12、18 和 24 个月评估角膜内皮细胞密度、眼内压和最佳矫正视力。分析成功率、滤泡修正率和并发症。完全成功定义为眼内压降低≥20%,并达到目标眼压≤18、≤15 或≤12mmHg,无需抗青光眼药物。合格成功表示在有或没有药物的情况下达到了标准。

结果

术后 24 个月内角膜内皮细胞无明显下降(p>0.05)。术后眼内压显著降低(p<0.001),从 29.6±8.3mmHg 降至 24 个月时的 13.0±4.3mmHg(p<0.001)。术后 24 个月,目标眼压≤15mmHg 的完全成功率和合格成功率分别为 52.9%和 54.6%。术后 24 个月最佳矫正视力无变化。

结论

Preserflo MicroShunt 对角膜内皮细胞没有负面影响,在 2 年的时间内,对开角型青光眼患者显示出良好的成功率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c1/11584475/8bddf2f7af8e/417_2024_6508_Fig1_HTML.jpg

相似文献

2
Efficacy, Confounders and Safety of the Preserflo Microshunt.
Klin Monbl Augenheilkd. 2024 Sep;241(9):1048-1056. doi: 10.1055/a-2325-9286. Epub 2024 Jul 24.
3
Early Results of Preserflo MicroShunt for Primary Open Angle Glaucoma in White Patients.
J Glaucoma. 2025 Feb 1;34(2):103-113. doi: 10.1097/IJG.0000000000002509. Epub 2024 Oct 11.
4
Short-term efficacy and safety of PreserFlo MicroShunt in Japanese patients with medically treated primary open-angle glaucoma.
Jpn J Ophthalmol. 2025 Mar;69(2):287-295. doi: 10.1007/s10384-024-01159-y. Epub 2025 Jan 18.
5
Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery.
Cesk Slov Oftalmol. 2025;81(4):189-196. doi: 10.31348/2025/9.
6
Long-term Outcomes of PreserFlo MicroShunt versus XEN45 Gel Stent in Open-Angle Glaucoma.
Klin Monbl Augenheilkd. 2024 Jul;241(7):805-812. doi: 10.1055/a-2152-8455. Epub 2023 Sep 6.
7
Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study.
Ophthalmol Glaucoma. 2022 Mar-Apr;5(2):210-218. doi: 10.1016/j.ogla.2021.08.005. Epub 2021 Aug 31.
9
Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study.
Ophthalmology. 2021 Dec;128(12):1710-1721. doi: 10.1016/j.ophtha.2021.05.023. Epub 2021 May 27.
10
Histopathological findings of failed blebs after microinvasive bleb surgery with the XEN Gel Stent and Preserflo MicroShunt.
Graefes Arch Clin Exp Ophthalmol. 2024 Sep;262(9):2977-2984. doi: 10.1007/s00417-024-06479-w. Epub 2024 Apr 16.

引用本文的文献

1
3-year real-world outcomes of standalone PreserFlo MicroShunt implantation - effectiveness and safety profile.
Graefes Arch Clin Exp Ophthalmol. 2025 Jul 31. doi: 10.1007/s00417-025-06928-0.
2
Preserflo™ microshunt for the treatment of refractory childhood glaucoma: A case series study.
Am J Ophthalmol Case Rep. 2025 Jul 8;39:102384. doi: 10.1016/j.ajoc.2025.102384. eCollection 2025 Sep.
3
Rapid Corneal Endothelial Cell Loss After PreserFlo MicroShunt Surgery: A Case Report.
Cureus. 2025 Apr 27;17(4):e83091. doi: 10.7759/cureus.83091. eCollection 2025 Apr.
5
Preserflo-MicroShunt: Postoperative Effects on Endothelial Cell Density and Corneal Thickness.
Biomedicines. 2025 Feb 5;13(2):364. doi: 10.3390/biomedicines13020364.
6
The Road Less Traveled: Ciliary Sulcus Implantation of the Preserflo MicroShunt.
Case Rep Ophthalmol. 2025 Jan 30;16(1):68-73. doi: 10.1159/000543219. eCollection 2025 Jan-Dec.
7
One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge.
Ophthalmol Ther. 2025 Jan;14(1):153-167. doi: 10.1007/s40123-024-01074-y. Epub 2024 Nov 22.

本文引用的文献

1
Preserflo MicroShunt: Efficacy and Endothelial Cell Density.
J Glaucoma. 2023 Dec 1;32(12):1018-1021. doi: 10.1097/IJG.0000000000002325. Epub 2023 Oct 17.
2
PRESERFLO ™ MicroShunt versus trabeculectomy: 1-year results on efficacy and safety.
Graefes Arch Clin Exp Ophthalmol. 2023 Oct;261(10):2901-2915. doi: 10.1007/s00417-023-06075-4. Epub 2023 May 3.
3
Clinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United Kingdom.
Ophthalmol Glaucoma. 2023 Jul-Aug;6(4):342-357. doi: 10.1016/j.ogla.2022.11.006. Epub 2022 Nov 23.
4
A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants.
Ther Adv Ophthalmol. 2022 Oct 10;14:25158414221125697. doi: 10.1177/25158414221125697. eCollection 2022 Jan-Dec.
5
Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
J Glaucoma. 2022 Jul 1;31(7):557-566. doi: 10.1097/IJG.0000000000002052. Epub 2022 May 17.
6
Short-term safety and efficacy of Preserflo™ Microshunt in glaucoma patients: a multicentre retrospective cohort study.
Eye (Lond). 2023 Mar;37(4):644-649. doi: 10.1038/s41433-022-01995-7. Epub 2022 Mar 12.
7
PreserFlo MicroShunt: An Overview of This Minimally Invasive Device for Open-Angle Glaucoma.
Vision (Basel). 2022 Feb 9;6(1):12. doi: 10.3390/vision6010012.
8
Endothelial cell loss 5 years after Preserflo MicroShunt implantation: About two cases.
Am J Ophthalmol Case Rep. 2021 Dec 8;25:101238. doi: 10.1016/j.ajoc.2021.101238. eCollection 2022 Mar.
10
Evaluation of the Ultrastructural and In Vitro Flow Properties of the PRESERFLO MicroShunt.
Transl Vis Sci Technol. 2021 Nov 1;10(13):26. doi: 10.1167/tvst.10.13.26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验